- About us
- About Vaccines
- Media centre
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Breakthroughs only come about because of the passion, commitment and dedication of individuals, teams and companies working to discover and develop new vaccines for patients.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
Vaccination is one of the most cost-effective public health interventions ever implemented, significantly decreasing the worldwide incidence of numerous deadly diseases and associated mortality. To ensure the continuous and optimal protection of all citizens against infectious vaccine-preventable diseases, taking into consideration the ageing population, better access to immunisation should be ensured and provided throughout Europe. Expanding convenient access to vaccine administration should go together as a shared responsibility to vaccinate with all other Health Care Providers, HCPs (Doctors/GPs, nurses, midwives, pharmacists etc).
Find the VE paper on Improving Access and Convenience to Vaccination here.
The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The objective is to promote and foster a younger generation of scientists in the early stages of their career.
The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of the immune response, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).
The Innovative Medicines Initiative (IMI) is celebrating its 10th anniversary with a high-level event. Organised jointly by IMI together with the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the event will take place at the European Commission’s Charlemagne Building in Brussels, Belgium on Wednesday 27 June 2018 from 13:00 to 18:00.
Vaccines Europe welcomes the European Commission Proposal for a Council Recommendation and the Commission Communication on Strengthened Cooperation against Vaccine Preventable Diseases. See the full statement here.